Results 31 to 40 of about 5,671 (151)
Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
Ductal adenocarcinoma of the prostate is a rare histological variant that only represents
Edgar Linden-Castro +5 more
doaj +1 more source
Prostate patient‐derived organoids (PDOs) were established from TURP and biopsy specimens with >90% success and retain key features of their tissues of origin, making them functional avatars for antisense oligonucleotide (ASO) therapy . Transfecting single cells outside the Matrigel matrix and then reconstituting organoids overcomes the 3D delivery ...
Thi Thom Tran +15 more
wiley +1 more source
Introduction. The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents. In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to ...
Yutaka Yamamoto +7 more
doaj +1 more source
Abiraterone Acetate Withdrawal Syndrome: Does It Exist
In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy.
Hélène Gauthier +3 more
doaj +1 more source
ABSTRACT Introduction We report a case of de novo prostatic adenosquamous carcinoma with a minute squamous component in the initial biopsy and early liver metastasis despite a marked prostate‐specific antigen response. Case Presentation A 72‐year‐old man was diagnosed with locally advanced prostate cancer with nodal and multiple bone metastases ...
Yohei Tsubouchi +9 more
wiley +1 more source
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone ...
Benjamin A. Gartrell, Fred Saad
doaj +1 more source
Background. The ever-increasing prevalence of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) presents an alarming challenge to existing tuberculosis (TB) treatment stratgies.
Muhammad Fayaz Khan +6 more
doaj +1 more source
ABSTRACT Lethal prostate cancer (PCa) is dominated by treatment‐refractory progression in bone. In this study, we used plasma‐derived extracellular vesicles (EVs) for monitoring the tumour and therapy‐induced changes in the bone tumour microenvironment (bone‐TME) in men with bone metastatic PCa (M1b PCa).
Emanuela Gentile +11 more
wiley +1 more source
Objective: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic ...
Dingwei Ye +16 more
doaj +1 more source
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi +8 more
wiley +1 more source

